The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology.

[1]  C. Bedrossian.  Special stains, the old and the new: The impact of immunocytochemistry in effusion cytology , 1998, Diagnostic cytopathology.

[2]  G. Viale,et al.  Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. , 1997, Acta cytologica.

[3]  A. Hjerpe,et al.  Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[4]  B. Schwaller,et al.  Heterogeneity of expression of the calcium-binding protein calretinin in human colonic cancer cell lines. , 1996, Anticancer research.

[5]  I. Ramzy,et al.  Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1. , 1996, Acta cytologica.

[6]  B. Schwaller,et al.  Change of calretinin expression in the human colon adenocarcinoma cell line HT29 after differentiation. , 1996, Biochimica et biophysica acta.

[7]  G. Viale,et al.  Calretinin: a novel immunocytochemical marker for mesothelioma. , 1996, The American journal of surgical pathology.

[8]  P. Vogt,et al.  The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. , 1996, Pathology, research and practice.

[9]  I. Ramzy,et al.  p53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells. , 1996, Acta cytologica.

[10]  S. Paulsen,et al.  The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma. , 1994, Pathology, research and practice.

[11]  P. Devine,et al.  Markers for metastatic adenocarcinoma in serous effusion specimens , 1994, Diagnostic cytopathology.

[12]  S. Poppema,et al.  Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. , 1994, Archives of pathology & laboratory medicine.

[13]  D. Allred,et al.  Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. , 1993, Human pathology.

[14]  N. Ordóñez,et al.  Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. , 1992, The American journal of pathology.

[15]  B. Schwaller,et al.  Expression of the calcium binding protein calretinin in WiDr cells and its correlation to their cell cycle. , 1992, Experimental cell research.

[16]  A. Donna,et al.  Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial‐cell antibody , 1992, Diagnostic Cytopathology.

[17]  A. Leong,et al.  Cytopathology of malignant mesothelioma: A stepwise logistic regression analysis , 1992, Diagnostic cytopathology.

[18]  M. Gaffey,et al.  Immunoreactivity for BER‐EP4 in Adenocarcinomas, Adenomatoid Tumors, and Malignant Mesotheliomas , 1992, The American journal of surgical pathology.

[19]  T. H. van der Kwast,et al.  Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma , 1991, The Journal of pathology.